Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-2409 + Prodrug + ICI in Stage III/IV NSCLC
NCT04495153Phase 2Active, not recruiting
- Sponsor
- Candel Therapeutics
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of aglatimagene besadenovec in non-small cell lung cancer (NSCLC), sponsored by Candel Therapeutics. Started Oct 2020; status: active, not recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04495153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495153.